CRISPR Therapeutics AG (CRSP)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-03) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-04) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-10) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-04) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-11) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-05) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-05) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-21) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive (loss) Income | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Shareholders' Equity | ||
| Consolidated Statements of Shareholders' Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| 401 (k) Savings Plan | — |
|
| Accrued Expenses | ||
| Basis of Presentation and Significant Accounting Policies | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Debt | — |
|
| Equity-based Compensation | — |
|
| Fair Value Measurement | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Leases | — |
|
| Marketable Securities | ||
| Net (loss) Income Per Share Attributable To Common Shareholders | — |
|
| Net Loss Per Share Attributable To Common Shareholders | ||
| Organization and Operations | — |
|
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | ||
| Segment Information | ||
| Share Capital | ||
| Significant Contracts | ||
| Stock-based Compensation | — |
|
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies and Basis of Presentation | — |
|